Rating Change
Evercore ISI Group reiterated its Outperform rating on Charles River Laboratories International, Inc. (NYSE:CRL) on November 05, 2026.
reiterateNYSE:CRL
Evercore ISI Group Reiterates Outperform Rating on Charles River Laboratories International, Inc. (CRL)
Evercore ISI Group reiterated its Outperform rating on Charles River Laboratories International, Inc. (NYSE:CRL) on November 05, 2026.
At publication ·
What changed
Charles River Laboratories International, Inc. (NYSE:CRL) · reiterate
- Firm
- Evercore ISI Group
- Rating
- Outperform to Outperform
- Price at event
- $322.16
- Market capitalization
- $9.6B
At a glance
Key takeaways
- Evercore ISI Group reiterated an Outperform rating on Charles River Laboratories on November 5, 2026.
- CRL stock trades at $322.16 with a $9.6 billion market cap and gained 51.4% over the past 52 weeks.
- Among the 10 most recent analyst ratings, 9 are Buy, 1 is Hold, and 0 are Sell recommendations.
- Analyst ratings provide one input for investment decisions but have mixed predictive power on their own.
Market Context
Charles River Laboratories International, Inc. operates in the Healthcare sector. The stock currently trades at $322.16 with a market capitalization of $9.6B. The stock has gained 51.4% over the past 52 weeks.
Analyst coverage from Evercore ISI Group provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Charles River Laboratories International, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Charles River Laboratories International, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 05, 2026 | Evercore ISI Group | Outperform | N/A |
| Oct 13, 2026 | Morgan Stanley | Overweight | N/A |
| Sep 30, 2026 | UBS | Buy | N/A |
| Sep 28, 2026 | Jefferies | Buy | N/A |
| Sep 25, 2026 | Deutsche Bank | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View CRL Stock Page
Frequently Asked Questions
What does the Outperform rating mean for CRL?
A rating of Outperform from Evercore ISI Group reflects the analyst's outlook on Charles River Laboratories International, Inc. (NYSE:CRL). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CRL forecast page.
Loading related coverage…
